INTRODUCTION
Venous ulcers (VUs) represent 70% of lower limb ulcers, with a prevalence of 0.06 to 2% in the population. 1 They constitute a serious public health problem, which contributes to burden public spending in the Brazilian public healthcare system, as well as interfering in the quality of life of the population due to complications that may result in significant morbidity. 2 Despite the high prevalence and its importance, it is often neglected and approached inappropriately. 3 Studies aiming at rapid healing strategies are important.
Due to the difficult healing, VUs need a correct diagnostic and therapeutic approach. In this sense, many products have been developed for healing, such as the homologous platelet gel (PG), obtained from the concentrated blood platelet, exceeding from blood transfusion. 4 This strategy aims to obtain an effective dressing by means of the release of growth factors in the wound bed, with the advantage of having low cost.
This study aimed to evaluate the safety and efficacy of homologous PG in VU comparing it with the hydrocolloid dressing. The inclusion criteria were: participants aged >18 years with VU, presence of good granulation tissue, defined as having a bright red color. Exclusion criteria were: presence of associated peripheral arterial disease, characterized when the ankle-brachial index was lower than 0.9, history of osteomyelitis and presence of critical colonization/ infection in the wound bed.
METHODS

This is
Randomization was generated using Microsoft Excel and, subsequently, matched envelopes were made, identified numerically and opened in sequential order at the time of inclusion of the patient. VUs were randomized and divided into groups using platelet gel (PG) and 
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The secondary dressing was changed daily at home and the primary dressing of both groups was changed every four days at home or at Longitudinal variables were evaluated according to the intention to treat population. Groups were compared through a generalized linear model of mixed effects, with unstructured covariance structure, gamma probability distribution (identity) and robust analysis. Experimental unit of analysis used was the ulcerated area in cm 2 .
Data were analyzed in IBM SPSS 22.0 software. Statistical significance was determined at 5%.
RESULTS
Sixteen participants were included, with a total of 21 VUs:
9 ulcers were randomized to the PG group and 12 to the HC group.
Demographic and clinical characteristics of patients and characteristics of lesions are presented in table 1.
In the studied population, women (63%) predominated, with a mean age of 62.3 years, with systemic arterial hypertension being the most frequent comorbidity (50%). The history of ulcer recurrence was 76%.
Lesions had a median of 24 months of active ulcer time, predominantly on the lateral side (62%) and thicker margins (62%).
Lower limb edema was the most frequent perilesional characteristic (63%). The groups did not differ in the initial size of the ulcers (p = 0.13), nor their duration (p = 0.81).
It should be noted the homogeneity in clinical and demographic parameters (except age), the reduction of areas in both groups, the absence of effects due to treatments and the low percentage of adverse events at follow-up (Table 2 ).
There were no ulcers at the time evaluated that presented complete healing.
Individual measurements of VU area at each visit are shown in graph 1. Both treatments promoted a significant reduction (p<0.01) in the areas of the ulcers in 90 days (mean 69%) and there was a significant difference between the groups regarding progressive reduction of ulcer areas favoring HC (70% vs. 64%, p<0.01).
When adjusted for age, varicose veins and recurrence of ulcers, variables in which the groups were different at p<0.20, the statistical difference between the groups (p <0.01) was maintained, favoring treatment with HC.
Regarding neovascularization, biopsies of 9 participants were analyzed, totaling 10 VUs, 7 of the HC group and 3 of the PG group, who remained in the study until D 90 ( Figure 2 ). There was no difference between the groups in the evaluation of the scores between D 0 and D 90 (p = 0.67).
Observed characteristics of both dressings were described in chart 1. On the use of homologous PG, there are few studies on venous ulcers. Bernuzzi et al. 8 , using autologous and homologous PG in ulcers of different etiologies, verified area reduction of >50% in the period of 96 days. Frykberg et al. 9 , using autologous platelet-rich plasma in ulcers of different etiologies, found improvement in 97%
DISCUSSION
of the lesions, with a mean area reduction of 39.5%. In another similar study, with the use of autologous platelet-rich plasma, the area reduction found was 47.5% in 86.3% of lesions. 10 The healing effects of PG can be attributed to the release of innumerable growth factors after platelet activation, which suggests that the therapy is similar to natural healing by the application of multiple growth factors in a biological way. cess, including EGF, PDGF, FGF, TGF-β1 and IGF-1.
12
Choosing to use the homologous PG is due to its low cost, since it uses surplus platelet of blood transfusion, and also due to the comfort to the patient. Shan et al. 11 reported that the preparation and storage of autologous PG limit its clinical use, because in addition to being uncomfortable to the patient, for each application it is necessary a new blood collection, which stimulates the homologous PG proposal.
Demographic and clinical characteristics were homogeneous between the groups, except for age, and agreed with those reported in previous studies, such as women predominance, age around 60 years and hypertension as the more frequent comorbidity. 13 Lesion and perilesional characteristics, as well as the history of ulcer recurrence, are those commonly found in patients with VUs.
In general, VUs have an irregular shape, with well-defined borders, which can become deep with yellowish exudate, and present eczema, ocher dermatitis and perilesional lipodermosclerosis. 3 Prevalence of recurrence was 76%; a study conducted by Finlayson et al. 14 found 78% of VU recurrence in patients followed up for three years, having as risk factors history of deep vein thrombosis, multiple anterior leg ulcers and a longer duration of anterior ulcer.
It was observed that PG presented adverse events, such as critical colonization and increased area, but without statistical difference in relation to HC group. This is probably due to the fact that Our study has limitations: it is unicentric, with a small number of patients, which made impossible a more precise evaluation of PG.
CONCLUSION
Homologous platelet gel associated with compressive treat- 
